Clinical Trials Browser

INDUSTRY × Glucose Intolerance × pembrolizumab × Clear all

NCT04373265 2024-02-23

Study of Relacorilant in Combination With Pembrolizumab for Patients With Adrenocortical Carcinoma Which Produces Too Much Stress Hormone (Cortisol)

ACTH Syndrome, Ectopic, Adrenal Cortex Neoplasms, Adrenal Gland Diseases, Adrenocortical Hyperfunction, Cushing Syndrome, Diabetes Mellitus, Type 2, Endocrine System Diseases, Hyperglycemia, Hypertension, Pathologic Processes, Glucose Intolerance, Adrenocortical Carcinoma